No CrossRef data available.
Article contents
Sabril
Published online by Cambridge University Press: 18 September 2015
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0317167100033333/resource/name/firstPage-S0317167100033333a.jpg)
- Type
- Other
- Information
- Copyright
- Copyright © Canadian Neurological Sciences Federation 1997
References
References:
1.Grant, SM and Heel, RC. Vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs, 1991;41(6):889–926.CrossRefGoogle ScholarPubMed
2.Arzimanoglou, AA, Dumas, C, Chirardl, L et coll. Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. Epilepsia. 1995;36(S3).Google Scholar
3.Reynolds, EH, Ring, HA, Farr, IN et coll. Open, double-blind and long-term study of vigabatrin in chronic epilepsy. Epilepsia, 1991;32(4):530–538.CrossRefGoogle ScholarPubMed
4.Dodrill, CB, Arnett, JL, Sommerville, KW and Sussman, NM. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia, 1995;36(2):164–173.Google ScholarPubMed